Dopamine agonists and cobalt-induced epilepsy in the rat
- PMID: 497536
- PMCID: PMC2044019
- DOI: 10.1111/j.1476-5381.1979.tb08687.x
Dopamine agonists and cobalt-induced epilepsy in the rat
Abstract
1 Electrocorticogram (ECoG) recordings were made from conscious rats which had cortical implants of cobalt. The epileptiform spike activity was then assessed by means of an automated technique, based on peak angle measurements. 2 Apomorphine (0.5, 1.0 and 2.0 mg/kg i.p.) and lisuride (0.1, 0.25, 0.5 and 1.0 mg/kg i.p.) inhibited spike activity in established primary and secondary foci in a dose-dependent manner. Bromocryptine (10 and 20 mg/kg i.p.) and CF 25-397 (40 mg/kg i.p.) had a similar effect but only after a latent period of several hours. Chronic administration of bromocryptine (20 mg/kg i.p. daily) attenuated the normal development of the foci following implantation. 3 Pimozide (1 mg/kg i.p.) potentiated cortical epileptic activity in cobalt-implanted rats and blocked the antiepileptic effects induced by the dopamine agonists. 4 Intrastriatal administration of dopamine (25 micrograms) or apomorphine (60 micrograms) suppressed epileptiform spikes in the cortex. Destruction of striatal catecholamine terminals by 6-hydroxydopamine increased the spike activity. 5 It is concluded that the striatum may play an essential part in mediating the anti-epileptic effects of dopamine and its agonists in this model of epilepsy.
Similar articles
-
Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.Exp Neurol. 1999 Feb;155(2):204-20. doi: 10.1006/exnr.1998.6996. Exp Neurol. 1999. PMID: 10072296
-
Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-DOPA.Br J Pharmacol. 1976 Jan;56(1):59-68. doi: 10.1111/j.1476-5381.1976.tb06959.x. Br J Pharmacol. 1976. PMID: 943193 Free PMC article.
-
Lisuride and transdihydrolisuride: differences in action on central dopaminergic functions in dependence on the location and the state of receptors.Pol J Pharmacol Pharm. 1985 May-Jun;37(3):263-71. Pol J Pharmacol Pharm. 1985. PMID: 4070078
-
Reduced sensitivity of synaptosomal dopamine autoreceptors following increase in synaptosomal dopamine synthesis.Eur J Pharmacol. 1985 Mar 12;109(3):433-4. doi: 10.1016/0014-2999(85)90410-8. Eur J Pharmacol. 1985. PMID: 3987811 No abstract available.
-
Experimental and clinical approaches to treatment of hypertension by dopamine receptor agonists.Clin Exp Hypertens A. 1987;9(5-6):1069-84. doi: 10.3109/10641968709161466. Clin Exp Hypertens A. 1987. PMID: 3304729 Review.
Cited by
-
The Synergistic Effect of Raloxifene, Fluoxetine, and Bromocriptine Protects Against Pilocarpine-Induced Status Epilepticus and Temporal Lobe Epilepsy.Mol Neurobiol. 2019 Feb;56(2):1233-1247. doi: 10.1007/s12035-018-1121-x. Epub 2018 Jun 7. Mol Neurobiol. 2019. PMID: 29881945
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources